Nordic Life Science Days (NLSDays), this year held in Stockholm, includes not only great networking opportunities, but nine interesting super sessions.
The 2½-day annual NLSDays offers plenty of opportunities for networking and is expected to attract more than 1,200 delegates from all over the world.
“Nordic Life Science Days has become the region’s premier partnering event for the life science industry and similar to the previous five years, we offer an excellent conference program tuning in on topics like digital solutions, artificial intelligence, drug delivery, progress in precision medicine and immune-oncology,” says Jonas Ekstrand, Director General at SwedenBIO, the Swedish life science industry organization. “The increasing number of scheduled meetings we have seen year by year confirms that Nordic Life Science Days meets an important need for Nordic start-ups, established international life science companies and global investors, alike.”
Super Sessions tackle the Big questions
The super sessions of this year’s NLSDays are zooming in on several potential solutions to some of healthcare’s major challenges. International experts will share their insight and views when it comes to new types of treatments and preventive measures governed by innovations within e.g. digital solutions, big data, artificial intelligence, immune-oncology, drug-delivery and nano- and other technologies. Furthermore, this year’s super sessions also discuss alternative ways for financing projects, ensuring patient engagement and defining the roles of stakeholders when introducing personalized medicine concepts.
The super sessions are: Financing, Return on Engagement, CrossRoads in BioPharma and HealthTech, Precision Medicine, Drug Delivery of the Future, International Investors Pitching, Reproductive Medicine, Catching the Immuno-oncology wave and Artificial Intelligence in Life Science.
NLSDays is a SwedenBIO event, produced by Bionordic. Nordic Life Science Days has grown since its launch in 2012 to become the largest Nordic partnering conference for the global life science industry. In 2017, 1300 delegates from 40 countries attended the meeting. The 800 companies attending engaged in over 3000 one-on-one meetings.
Among the Big Pharma, investors and other major players registered for the meeting so far are AstraZeneca, MSD, Pfizer, Sanofi, SOBI, Boehringer Ingelheim, Roche, Bristol-Mayer Squibb, Bayer, Novo, Johnson & Johnson Innovation, GE Healthcare, DNB, Industrifonden, HealthCap, BioGeneration Ventures, Almi Invest, Gilde Healthcare, Gimv, Lundbeckfonden Ventures, Seventure Partners, IBM and IQVIA,
Venue: Stockholm Waterfront Congress Center, Nils Ericssons Plan 4, Stockholm, Sweden.
Time: September 10-12, 2018